	US 12,343,428 B2
	Compositions and methods for cancer treatment
Mark Kester, Afton, VA (US); Pedro Filipe Da Costa Pinheiro, Charlottesville, VA (US); and Jeremy Shaw, Charlottesville, VA (US)
Assigned to University of Virginia Patent Foundation, Charlottesville, VA (US)
Appl. No. 16/761,114
Filed by University of Virginia Patent Foundation, Charlottesville, VA (US)
PCT Filed Nov. 5, 2018, PCT No. PCT/US2018/059259 § 371(c)(1), (2) Date May 1, 2020, PCT Pub. No. WO2019/090255, PCT Pub. Date May 9, 2019.
Claims priority of provisional application 62/581,179, filed on Nov. 3, 2017.
Prior Publication US 2020/0268665 A1, Aug. 27, 2020
Int. Cl. A61K 9/1271 (2025.01); A61K 31/4174 (2006.01); A61K 31/58 (2006.01); A61P 35/00 (2006.01); A61K 31/138 (2006.01); A61K 31/165 (2006.01); A61K 45/06 (2006.01)

CPC A61K 9/1271 (2013.01) [A61K 31/4174 (2013.01); A61K 31/58 (2013.01); A61P 35/00 (2018.01); A61K 31/138 (2013.01); A61K 31/165 (2013.01); A61K 45/06 (2013.01)]

20 Claims

1. A method for treating Prostate Cancer (PCa) in a subject, the method comprising administering to the subject an effective amount of a ceramide nanoliposome (CNL), wherein the CNL comprises a lipid bilayer comprising one or more C₂-C₂₄ceramides and optionally encapsulates an inhibitor of androgen synthesis, an inhibitor of androgen receptor (AR) signaling, or any combination thereof.